Buruli ulcer;Úlcera de Buruli

Anais Brasileiros de Dermatologia

Volumn 85, Issue 3, 2010, Pages 281-301

  Boleira, Manuela ^a   Lupi, Omar ^b,c   Lehman, Linda ^d,e,f,g   Asiedu, Kingsley Bampoe ^g   Kiszewski, Ana Elisa ^h,i  

^a Primatological Center of Rio de Janeiro (CPRJ FEEMA)   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Carlos Chagas Post Graduate Medical Institute   (Brazil)

^d American Leprosy Missions   (United States)

^e Veterinary Dentistry and Oral Surgery   (United States)

^f EMORY UNIVERSITY   (United States)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

^h Chest Medicine Health Science University   (Brazil)

ⁱ Santa Casa Complexo Hospitalar   (Brazil)

Author keywords

Buruli ulcer; Mycobacterium infections, atypical; Mycobacterium ulcerans; World Health Organization

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; RIFAMPICIN; STREPTOMYCIN;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANOREXIA; ANTIBIOTIC THERAPY; ASPIRATION BIOPSY; ATYPICAL MYCOBACTERIOSIS; BACTERIUM CULTURE; BRAZIL; BURULI ULCER; CLINICAL FEATURE; CLINICAL PRACTICE; CONTINUING EDUCATION; DIET; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE COURSE; DIZZINESS; DRUG WITHDRAWAL; ENDEMIC DISEASE; EXERCISE; GEOGRAPHIC DISTRIBUTION; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPOACUSIS; IMMUNE RESPONSE; INCIDENCE; JAUNDICE; JOINT CONTRACTURE; MYCOBACTERIUM ULCERANS; NAUSEA; NONHUMAN; NUTRITION; NYSTAGMUS; PATIENT MONITORING; PERSONAL HYGIENE; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PROGNOSIS; PURPURA; RECOMMENDED DRUG DOSE; REVIEW; SHOCK; SKIN GRAFT; SKIN MANIFESTATION; SKIN ULCER; ULCER HEALING; VERTIGO; WORLD HEALTH ORGANIZATION; WOUND DRESSING; WOUND HEALING;

BURULI ULCER; HUMANS;

EID: 77955643954     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962010000300002     Document Type: Review

References (62)

1. Fenner F. The significance of the incubation period in infectious diseases. Med J Aust. 1950;2:813-8.
2. Wansbrough-Jones M, Phillips R. Buruli ulcer: emerging from obscurity. Lancet. 2006;367:1849-58.
3. George KM, Chatterjee D, Gunawardana G, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999; 283:854-57.6 (Pubitemid 129501127)
4. Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Guédénon A, et al. Mycobacterium ulcerans disease (Buruli ulcer) as seen in a rural hospital of southern Benin, 1997-2001. Emerg Infect Dis. 2004;10:1391-8.
5. Stienstra Y, Dijkstra PU, Guédénon A, Johnson RC, Ampadu EO, Mensah T, et al. Development of a questionnaire assessing Buruli ulcer-induced functional limitation. Am J Trop Med Hyg. 2004;70:318-22. (Pubitemid 38366539)
6. Stienstra Y, Dijkstra PU, van Wezel MJ, van Roest MH, Beets M, Zijlstra IJ, et al. Reliability and validity of the Buruli ulcer Functional Limitations Score (BUFLS) Questionnaire. Am J Trop Med Hyg. 2005;72:449-52. (Pubitemid 41278856)
7. WHO, Programmes and projects, Media centre, Fact sheet No199 - Buruli ulcer disease (Mycobacterium ulcerans infection) - Revised in March 2007 Available from: http://www.who.int/mediacentre/factsheets/fs199/en/index.html
8. van der Werf TS, Stienstra Y, Johnson RC, Phillips R, Adjei O, Fleischer B, et al. Mycobacterium ulcerans disease. Bull World Health Organ. 2005;83:785-91.
9. Asiedu K, Etuaful S. Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Am J Trop Med Hyg. 1998;59:1015-22. (Pubitemid 29028938)
10. Stienstra Y, van der Graaf WTA, Asamoa K, van der Werf TS. Beliefs and attitudes toward Buruli ulcer in Ghana. Am J Trop Med Hygiene. 2002;67: 207-13. (Pubitemid 135715338)
11. Maccallum P, Tolhurst JC, Buckle G, Sissons HA. A new mycobacterial infection in MA. J Path Bact. 1948;60:93-122.
12. Coloma JN, Navarrete-Franco G, Iribe P, López-Cepeda LD. Ulcerative cutaneous mycobacteriosis. Int J Leprosy. 2005;73:5-12.
13. dos Santos VM, Noronha FL, Vicentina EC, Lima CC. Mycobacterium ulcerans infection in Brazil. Med J Aust. 2007;187:63-4.
14. Portaels F, Silva MT, Meyers WM. Buruli ulcer. Clin zDermatol. 2009;27:291-305.
15. Clinical features and treatment of pre-ulcerative Buruli lesions (Mycobacterium ulcerans infection). Report II of the Uganda Buruli Group. Br Med J. 1970;2:390-3.
16. Johnson PD, Stinear TP, Hayman JA. Mycobacterium ulcerans - a mini-review. J Med Microbiol. 1999;48:511-3.
17. Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Scott JT, et al. Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health. 2004;9:1297-304. (Pubitemid 40037165)
18. Lupi O, Madkan V, Tyring SK. Tropical dermatology: Bacterial tropical diseases J Am Acad Dermatol. 2006;54:559-78.
19. Zeegelaar JE, Faber WR. Imported Tropical Infectious Ulcers in Travelers. J Clin Dermatol. 2008;9:219-32.
20. McGann H, Stragier P, Portaels F, Gascoyne Binzi D, Collyns T, Lucas S, et al. Buruli ulcer in United kingdom tourist returning from latin america. Emerg Infect Dis. 2009;15:1827-9.
21. Ezzedine K, Pistone T, Cottin J, Marsollier L, Guir V, Malvy D, et al. Buruli ulcer in long-term traveler to Senegal. Emerg Infect Dis. 2009;15:118-9.
22. Raghunathan PL, Whitney EA, Asamoa K, Stienstra Y, Taylor TH Jr, Amofah GK, et al. Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana. Clin Infect Dis. 2005;40:1445-53. (Pubitemid 40628632)
23. Marsollier L, Robert R, Aubry J, Saint André JP, Kouakou H, Legras P, et al. Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol. 2002;68:4623-8. (Pubitemid 34988148)
24. Johnson PD, Azuolas J, Lavender CJ, et al. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis 2007; 13: 1653-60. (Pubitemid 350126191)
25. Benbow ME, Williamson H, Kimbirauskas R, et al. Aquatic invertebrates as unlikely vectors of Buruli ulcer disease. Emerg Infect Dis 2008; 14: 1247-54.
26. Portaels F, Elsen P, Guimaraes-Peres A, Fonteyne PA, Meyers W. Insects in the transmission of Mycobacterium ulcerans infection. Lancet. 1999;353:986. (Pubitemid 29132618)
27. Meyers WM, Shelly WM, Connor DH, Meyers EK. Human Mycobacterium ulcerans infections developing at sites of trauma to skin. Am J Trop Med Hyg. 1974;23:919-23.
28. Debacker M, Zinsou C, Aguiar J, Meyers W, Portaels F. Mycobacterium ulcerans disease (Buruli ulcer) following human bite. Lancet. 2002;360:1830. (Pubitemid 35449421)
29. Debacker M, Zinsou C, Aguiar J, Meyers W, Portaels F. First case of Mycobacterium ulcerans disease (Buruli ulcer) following a human bite. Clin Infect Dis. 2003;36:e67-8.
30. Stienstra Y, van der Werf TS, Guarner J, Raghunathan PL, Spotts Whitney EA, van der Graaf WT, et al. Analysis of an IS2404-Based Nested PCR for Diagnosis of Buruli Ulcer Disease in Regions of Ghana Where the Disease Is Endemic. J Clin Microbiol. 2003;41:794-7. (Pubitemid 36184199)
31. Chemlal K, Huys G, Laval F, Vincent V, Savage C, Gutierrez C, et al. Characterization of an unusual Mycobacterium: a possible missing link between Mycobacterium marinum and Mycobacterium ulcerans. J Clin Microbiol. 2002;40:2370-80. (Pubitemid 34747335)
32. Stinear TP, Seemann T, Pidot S, Frigui W, Reysset G, Garnier T, et al. Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. Genome Res. 2007;17:192-200. (Pubitemid 46220764)
33. van der Werf TS, Stinear T, Stienstra Y, van der Graaf WT, Small PL. Mycolactones and Mycobacterium ulcerans disease. Lancet. 2003;362:1062-4.
34. Kiszewski A, Becerril E, Aguilar L, Kader I, Myers W, Portaels F, et al. The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol. 2006; 143:445-51.
35. Chemlal K, Huys G, Laval F, Vincent V, Savage C, Gutierrez C, et al. Characterization of an unusual Mycobacterium: a possible missing link between Mycobacterium marinum and Mycobacterium ulcerans. J Clin Microbiol. 2002;40:2370-80. (Pubitemid 34747335)
36. Mve-Obiang A, Lee RE, Portaels F, Small PL. Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun. 2003;71:774-83. (Pubitemid 36150771)
37. Pahlevan AA, Wright DJM, Andrews C, George KM, Small PLC, Foxwell BM. The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine prodution and NF-B funtion. J Immunol. 1999;163:3928-35. (Pubitemid 29450921)
38. Hernandez-Pando R, Orozco H, Sampieri A, Pavon L, Velasquillo C, Larriva-Sahd J, et al. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology. 1996;89:26-33.
39. Kiszewski A, Becerril E, Baquera J, Aguilar LD, Hernandez-Pando R. Expression of transforming growth factor-beta isoforms and their receptors in lepromatous and tuberculoid leprosy. Scand J Immunol. 2003;57:279-85. (Pubitemid 36356821)
40. Lagarrigue V, Portaels F, Meyers WM, Aguiar J. [Buruli ulcer: risk of bone involvement! Apropos of 33 cases observed in Benin.] Med Trop (Mars). 2000;60:262-6.
41. Noeske J, Kuaban C, Rondini S, Sorlin P, Ciaffi L, Mbuagbaw J, et al. Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg. 2004;70:520-6. (Pubitemid 38658146)
42. Sizaire V, Nackers F, Comte E, Portaels F. Mycobacterium ulcerans infection: control, diagnosis and treatment. Lancet Infect Dis. 2006;6:288-96.
43. Portaels F, Johnson P, Meyers W. Histophatological methods for diagnosis of M. ulcerans disease. Buruli ulcer: Diagnosis of Mycobacterium ulcerans disease. 2001; Geneva: WHO.
44. Guarner J, Bartlett J, Whitney E, Raghunathan P, Stienstra Y, Asamoa K, et al. Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis. 2003; 9:651-6. (Pubitemid 36676359)
45. Prasad R. Pulmonary sarcoidosis and chronic cutaneous atypical mycobacterium ulcer. Aust Fam Physician. 1993;22:755-8.
46. Portaels F, Aguiar J, Debacker M, Steunou C, Zinsou C, Guédénon A, et al. Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli ulcer). Clin Diagn Lab Immunol. 2002; 9:1389-91. (Pubitemid 35283312)
47. Lehman L, Simonet V, Saunderson P, Agbenorku P. Buruli Ulcer Prevention of disability (POD) [mono graph on the internet]. WHO. 2006.[cited 2010 Mar 29]. Available from: http://www.who.int/buruli/ information/publications/BU-0POD- presentation.pdf
48. World Health Organization [homepage]. International Classification of Functioning, Disability and Health. Geneva: WHO; c2010 [cited 2010 Mar 29]. Available from: http://www.who.int/classifications/icf/en/
49. Bafende AE, Lukanu NP, Numbi AN. Buruli ulcer in an AIDS patient. S Afr Med J. 2002;92:437.
50. Johnson RC, Ifebe D, Hans-Moevi A, Kestens L, Houessou R, Guédénon A, et al. Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study. AIDS. 2002;16:1704-05. (Pubitemid 34921126)
51. Duker AA, Portaels F, Hale M. Pathways of Mycobacterium ulcerans infection: a review. Environ Int. 2006;32:567-73.
52. World Health Organization [homepage]. Provisional guidance on the role specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). Geneva: WHO; c2010 [cited 2010 Mar 29]. Available from: http://www.who.int/buruli/ information/antibiotics/en/index.html
53. Hayman J, McQueen A. The pathology of Mycobacterium ulcerans infection. Pathology. 1985;17:594-600.
54. Siegmund V, Adjei O, Racz P, Berberich C, Klutse E, van Vloten F, et al. Dry-reagent-based PCR as a novel tool for laboratory confirmation of clinically diagnosed Mycobacterium ulcerans-associated disease in areas in the tropics where M ulcerans is endemic. J Clin Microbiol. 2005; 43:271-76. (Pubitemid 40096311)
55. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother. 2005;49:3182-6. (Pubitemid 41060558)
56. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a ran domized controlled trial. Lancet. 2010;375:664-72.
57. Johnson PDR. Should antibiotics be given for Buruli ulcer? Lancet. 2010;375:618-9. Comment on: Lancet. 2010;375:664-72.
58. Stienstra Y, Dijkstra PU, van Wezel MJ, van Roest MH, Beets M, Zijlstra IJ, et al. Reliability and validity of the Buruli ulcer Functional Limitations Score (BUFLS) Questionnaire. Am J Trop Med Hyg. 2005;72:449-52. (Pubitemid 41278856)
59. Lehman L, Saunderson P. Ten Tasks to Prevent Disability in Buruli Ulcer, Tasks for people affected by Buruli Ulcer who want to prevent disability - "I Can Do It!" American Leprosy Missions, 2009. (currently used in community based POD training and is being made into a flip chart which is expected to be adopted by WHO. Examples will be shown at the 2010 Geneva BU meeting)
60. Evans MR, Etuaful SN, Amofah G, Adjei O, Lucas S, Wansbrough-Jones MH. Squamous cell carcinoma secondary to Buruli ulcer. Trans R Soc Trop Med Hyg. 1999;93:63-4. (Pubitemid 29123725)
61. Minutilli E, Orefici G, Pardini M, Giannoni F, Muscardin LM, Massi G, et al. Squamous Cell carcinoma secondary to buruli ulcer. Dermatol Surg. 2007;33:872-5. (Pubitemid 47013534)
62. Portaels F, Aguiar J, Debacker M, Guédénon A, Steunou C, Zinsou C, et al. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun. 2004;72:62-5. (Pubitemid 38018161)